Drug Insights

Is Monomethyl fumarate approved by the FDA?

1 July 2024
3 min read

Yes, Monomethyl fumarate, known by the brand name Bafiertam, is FDA approved. The FDA approved Bafiertam for the treatment of relapsing forms of multiple sclerosis (MS) on April 28, 2020.

What is Monomethyl Fumarate?

Monomethyl fumarate is a medication used to treat relapsing forms of multiple sclerosis (MS) in adults. These forms include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It is classified as a selective immunosuppressant.

How Does Monomethyl Fumarate Work?

Monomethyl fumarate works by modulating the immune response, which is believed to help reduce the frequency of relapse and slow the progression of disability in people with multiple sclerosis. It is administered in the form of oral delayed-release capsules.

Dosage and Administration

Monomethyl fumarate is taken orally, with or without food. The typical dosing regimen involves a "starter dose" of 95 mg taken twice daily for the first 7 days, followed by a "maintenance dose" of 190 mg taken twice daily thereafter. It is important to swallow the capsules whole without crushing, chewing, or opening them.

Side Effects

Common side effects of monomethyl fumarate include:

  • Flushing (sudden warmth, redness, or tingling sensation)
  • Stomach pain, indigestion
  • Nausea, vomiting
  • Diarrhea

Serious side effects can occur, and it is important to contact a healthcare provider if you experience:

  • Signs of an allergic reaction (hives, difficulty breathing, swelling of face, lips, tongue, or throat)
  • Severe warmth, redness, burning, or itching under the skin
  • Liver problems (loss of appetite, stomach pain, tiredness, dark urine, jaundice)
  • Signs of infection (fever, chills, sweating, mouth sores, headache, confusion, neck stiffness, sensitivity to light, vomiting, severe diarrhea)
  • Symptoms of a herpes virus infection (flu-like symptoms, cold sores around the mouth, blistering rash, burning pain in the thigh or lower back)

Precautions

Before taking monomethyl fumarate, inform your doctor if you have had:

  • Low white blood cell counts
  • Any infection
  • Liver disease

Monomethyl fumarate is not recommended for individuals younger than 18 years old, or for those concurrently using dimethyl fumarate or diroximel fumarate.

Storage

Store unopened bottles of monomethyl fumarate capsules in a refrigerator, but do not freeze them. Once opened, store the bottle at room temperature away from moisture, heat, and light, and keep the capsules in the original bottle. Unused capsules should be discarded 3 months after first opening the bottle.

Conclusion

Monomethyl fumarate, approved by the FDA on April 28, 2020, is a significant medication for managing relapsing forms of multiple sclerosis. Its ability to modulate the immune system helps reduce relapse rates and manage the progression of the disease. As with any medication, it is crucial to follow the prescribed dosing regimen and consult with a healthcare provider about any side effects or concerns.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

EZHARMIA® Approved in Japan as First Dual EZH1/EZH2 Inhibitor for Peripheral T-Cell Lymphoma Therapy
Latest Hotspot
3 min read
EZHARMIA® Approved in Japan as First Dual EZH1/EZH2 Inhibitor for Peripheral T-Cell Lymphoma Therapy
1 July 2024
EZHARMIA® Receives Approval in Japan as the First Dual EZH1 and EZH2 Blocker for Peripheral T-Cell Lymphoma Therapy.
Read →
Is MenQuadfi approved by the FDA?
Drug Insights
3 min read
Is MenQuadfi approved by the FDA?
1 July 2024
MenQuadfi, a meningococcal conjugate vaccine, is FDA approved. The FDA granted approval for MenQuadfi on April 23, 2020.
Read →
vTv Therapeutics Begins Key CATT1 Study Enrollment for Cadisegliatin in Type 1 Diabetes
Latest Hotspot
3 min read
vTv Therapeutics Begins Key CATT1 Study Enrollment for Cadisegliatin in Type 1 Diabetes
1 July 2024
vTv Therapeutics Announces Enrollment of First Participant in CATT1 Key Study for Cadisegliatin in Type 1 Diabetes.
Read →
Is Trodelvy approved by the FDA?
Drug Insights
3 min read
Is Trodelvy approved by the FDA?
28 June 2024
Trodelvy (sacituzumab govitecan-hziy) received accelerated approval on April 22, 2020, for the treatment of relapsed or refractory metastatic triple-negative breast cancer (TNBC) in adults who have received at least two prior therapies for metastatic disease.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.